Skip to main content
Premium Trial:

Request an Annual Quote

TriLink Receives $100,000 SBIR Grant

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – TriLink BioTechnology said today it has received a $100,000 Phase I Small Business Innovation Research grant from the National Institutes of Health to develop a Hot Start approach for Ligase Chain Reaction.

With the grant, which lasts until July, the San Diego company will use chemically modified ligation components containing thermolabile protecting groups to eliminate problems often seen in LCR, including specificity issues and false-positive signals. The company hopes its approach will eventually lead to LCR replacing applications where traditional PCR, Gap-LCR, and PCR/ ligation combination approaches are too expensive, not applicable, or problematic, it said.

The grant is the fifth the company has received and follows a Phase II SBIR grant of $725,000 in June to continuing study DNA ligase.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.